Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis

Barrera, Lourdes; Montes-Servín, Edgar; E, Alejandro Barrera; Ramírez-Tirado, Laura Alejandra; Salinas-Parra, F.; Bañales-Mendez, J.L.; Sandoval-Ríos, Marisol; Arrieta, Óscar

doi:10.1093/annonc/mdu549

Cited by 66 publications

(62 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clustering analyses of pretreatment serum CAFs to classify patients into subgroups have been reported in renal cell carcinoma and non-small cell lung cancer [16,19], and several studies showed that a distinct CAF profile could predict clinical outcomes [15][16][17][18][19]. However, although associations between inflammatory cascades or angiogenic factors, such as VEGF, and clinical outcomes have been reported in GC [24], comprehensive Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup… 167 explorations of circulating factors and the relationships with clinical outcomes have not been published for GC.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies of CAFs have indicated that an understanding of the delicate networking of CAFs is necessary to correlate CAF levels to clinical outcomes, because the biological activity of circulating factors might be the result of the interactions of CAFs rather than the action of single CAFs [15][16][17][18][19]. A previous study in renal cell carcinoma identified 6 CAFs as significant predictive factors for the selection of a combination regimen of sorafenib and interferon-alpha compared to sorafenib alone [16].…”

Section: Discussionmentioning

confidence: 99%

“…The development of the optimal anti-tumor immunological strategy should begin with an exploration of immunological factors, such as cytokines and angiogenic factors (CAFs), which are associated with the tumor. To understand the immunological landscape of a tumor, subgroups have been defined on the basis of circulating CAFs and their clinical implications have been explored in solid tumors [15][16][17][18][19]. In renal cell carcinoma, 6 CAFs that were predefined as the ''angiogenic group'' were also identified as significant predictive factors for adding interferon-alpha treatment to sorafenib [16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer

et al. 2015

View full text Add to dashboard Cite

Background Little is known about cytokine and angiogenic factors (CAFs) in gastric cancer (GC) in terms of tumor classification and prognostic value. Here, we aimed to correlate CAF signature with overall survival (OS) in GC. Methods We measured pretreatment serum levels of 52 kinds of CAFs in 68 GC patients who were treated with fluoropyrimidine and platinum combination chemotherapy using multiplex bead immunoassays and enzyme-linked immunosorbent assay. We evaluated correlations between CAF levels and pathological features and OS. Results Three distinct patient groups were identified: one with high levels of proangiogenic factors, another with high levels of proinflammatory factors, and the other with high levels of both factors. Eleven CAFs [interleukin (IL)-2 receptor-alpha, growth-regulated alpha protein, hepatocyte growth factor, macrophage colony-stimulating factor, stromal cell-derived factor, IL-6, IL-8, IL-10, interferongamma, vascular endothelial growth factor, and osteopontin] were independently correlated with poor OS. Clustering analysis of these 11 CAFs revealed distinct high and low 11-CAF signature groups. High 11-CAF signature was associated with shorter OS (10.1 vs. 17.9 months, p = 0.026) along with poor performance status, and the presence of signet ring cell components in multivariate analysis of OS (HR 1.76, p = 0.029). The patients' traditional clinicopathological characteristics were not significantly different between the high and low 11-CAF signature groups. Conclusion Serum CAF profiling differentiated GC patient groups. A high 11-CAF signature could identify GC patients with a poor prognosis when treated with standard chemotherapy who need urgent new treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Two of these studies found out that the serum IL-29 levels were higher in the control group than those in the non-small cell lung cancer (NSCLC) patients, but there was no statistically significant difference [34,35]. We found that the difference between baseline serum IL-29 concentrations between GC patients and healthy controls was not statistically significant (p= 0.627), and furthermore, we concluded that patients without metastasis had higher serum IL-29 concentrations than the patients with metastasis (p=0.01).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer

et al. 2015

View full text Add to dashboard Cite

Many studies suggested that cytokines interleukin (IL)-29, IL-32, and tumor necrosis factor alpha (TNF-α) are implicated in the pathogenesis of malignancies. The purpose of this study was to determine the clinical significance of the serum levels of IL-29, IL-32, and TNF-α in gastric cancer (GC) patients. Fifty-eight GC patients and 20 age- and sex-matched healthy controls were enrolled into this study. The median age at diagnosis was 59.5 years (range 32-82 years). Tumor localization of the majority of the patients was antrum (n = 42, 72.4 %), and tumor histopathology of the majority of the patients was diffuse (n = 43, 74.1 %). The majority of the patients had stage IV disease (n = 41, 70.7 %). Thirty-six (62.1 %) patients had lymph node involvement. The median follow-up time was 66 months (range 1 to 97.2 months). The baseline serum IL-29 concentrations were not different between patients and controls (p = 0.627). The baseline serum IL-32 and TNF-α concentrations of the GC patients were significantly higher (for IL-32, p = 0.014; for TNF-α, p = 0.001). Gender, localization, histopathology, tumor, and lymph node involvement were not found to be correlated with serum IL-29, IL-32, and TNF-α concentrations (p > 0.05). Patients without metastasis (p = 0.01) and patients who responded to chemotherapy (p = 0.04) had higher serum IL-29 concentrations. Patients older than 60 years had higher serum IL-32 (p = 0.002). Serum IL-29, IL-32, and TNF-α levels were not associated with outcome (p = 0.30, p = 0.51, and p = 0.41, respectively). In conclusion, serum levels of IL-32 and TNF-α may be diagnostic markers, and serum IL-29 levels may be associated with good prognosis in patients with GC.

show abstract

“…Levels of IL-33 have been reported to be reduced in the plasma of non-small cell lung cancer patients relative to controls [105], and levels of IL-33 have also been shown to negatively correlate with tumour stage in multiple myeloma patients [106]. Interestingly, IL-33 has been observed to be increased in response to viral infection and to be important for the eradication of a viral insult, as it can differentiate CTLs into anti-viral CD8 + T cells [107].…”

Section: "Wounds That Do Not Heal" -Understanding the Role Of Il-33 Imentioning

confidence: 99%

Wounds that heal and wounds that don’t − The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis

Millar

O'Donnell

McInnes

et al. 2017

Seminars in Cell & Developmental Biology

View full text Add to dashboard Cite

Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis

Abstract: Our results provide evidence that complex cytokine networks may be used to identify patient subgroups with different prognoses in advanced NSCLC. These cytokines may represent potential biomarkers, particularly in the immunotherapy era in cancer research.

Cited by 66 publications

References 25 publications

Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer

Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer

Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer

Wounds that heal and wounds that don’t − The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis

Contact Info

Product

Resources

About